Cheiron, the operating system for drug programs, raised $8 million in a Seed round to build its proprietary Life Sciences Knowledge Graph (LKG) — a structured intelligence layer connecting the world’s biomedical, clinical, regulatory, patent, and commercial knowledge into a single model.
Cheiron says it is already helping clients across clinical development, regulatory affairs, competitive intelligence, and program leadership workflows to evaluate programs, align stakeholders, and make decisions with greater confidence.
With fresh funds, Cheiron plans to accelerate the development of its Life Sciences Knowledge Graph and expand its engineering, product, and life sciences teams.
“Every important decision in drug development depends on understanding what is known, what is assumed, what remains uncertain, and what has already been decided,” said Minseok Bae, CEO and co-founder of Cheiron. “We built Cheiron to make that state visible for the first time, so teams can spend less time assembling information and more time advancing therapies.”
Menlo Ventures led the Seed investment round with strategic support from industry veterans including Moderna co-founder and MIT Institute Professor Robert Langer; former Pfizer Chief Medical Officer Freda Lewis-Hall; Chai Discovery co-founder and CEO Josh Meier; former Starbucks CEO Laxman Narasimhan; and former Apple AI chief John Giannandrea.